| RGS1 — Regulator of G Protein Signaling 1 | |
|---|---|
| Symbol | RGS1 |
| Full Name | Regulator of G Protein Signaling 1 |
| Chromosome | 1q31.2 |
| NCBI Gene | 5996 |
| OMIM | 607070 |
| Ensembl | ENSG00000190125 |
| UniProt | Q08169 |
| Diseases | [Multiple Sclerosis](/diseases/multiple-sclerosis), [Autoimmune Disorders](/diseases/autoimmune), [Chronic Inflammation](/diseases/inflammation) |
| Expression | Lymphoid tissues, Spleen, Lymph nodes, Blood leukocytes |
RGS1 (Regulator of G Protein Signaling 1) is a member of the RGS protein family that functions as a GTPase-activating protein (GAP) for heterotrimeric G proteins. While primarily studied in immune cells, RGS1 has emerging relevance to neuroinflammation and neurodegenerative disease processes.
RGS1 encodes a 206-amino acid protein that accelerates the intrinsic GTPase activity of Gα subunits, thereby terminating G protein-coupled receptor (GPCR) signaling. The protein contains a conserved RGS domain that mediates protein-protein interactions with Gα subunits. Originally identified as an immediate-early gene induced by B-cell receptor engagement, RGS1 is predominantly expressed in lymphoid tissues and plays critical roles in immune cell chemotaxis and signaling.
RGS1 functions as a potent GAP for Gαi and Gαs subunits, accelerating GTP hydrolysis by 10-100 fold compared to intrinsic rates. This activity rapidly terminates GPCR signaling by promoting Gα-GTP reassociation with Gβγ dimers, effectively serving as a molecular timer for GPCR signal transduction.
In B cells and T cells, RGS1 modulates chemokine receptor signaling by controlling the duration and intensity of G protein-mediated responses. RGS1 expression is rapidly induced following immune cell activation, suggesting a feedback role in limiting excessive immune responses.
RGS1 critically regulates immune cell chemotaxis by controlling the signaling duration of chemokine receptors. This is essential for proper immune cell trafficking and positioning within lymphoid tissues and sites of inflammation.
RGS1 polymorphisms have been associated with multiple sclerosis (MS) susceptibility. The protein's role in immune cell trafficking and signaling suggests potential involvement in the autoimmune pathogenesis of MS, where immune cells infiltrate the central nervous system.
RGS1 expression alterations have been implicated in various autoimmune conditions including type 1 diabetes, celiac disease, and rheumatoid arthritis. These associations suggest RGS1 as a modulator of immune tolerance and autoimmunity.
Emerging evidence links RGS1 to neuroinflammatory processes. Since chronic neuroinflammation is a key contributor to neurodegenerative diseases including Alzheimer's and Parkinson's disease, RGS1 may represent a therapeutic target for modulating neuroinflammatory responses.
RGS1 exhibits high expression in lymphoid tissues including spleen, lymph nodes, and peripheral blood leukocytes. Lower expression is detected in various tissues including brain regions. In the brain, RGS1 expression is primarily in microglia and infiltrating immune cells during inflammatory conditions.
RGS1 represents a potential therapeutic target for: